Navigation Links
Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
Date:5/4/2009

-Preliminary Data from This Trial to be Presented at ASCO-

-First Phase II Trial in Bavituximab Cancer Program to Complete Patient Enrollment-

TUSTIN, Calif., May 4 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it has completed enrollment in its Phase II trial evaluating bavituximab in combination with docetaxel in advanced breast cancer patients. The planned 46 patients have been enrolled and are currently undergoing treatment and follow-up. The primary objective of the multi-center, open-label Phase II study is to assess the overall response rate to bavituximab and docetaxel. The company also announced that preliminary data from this trial has been accepted for oral presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.

"Completion of patient enrollment in this Phase II study in advanced breast cancer patients represents a milestone for Peregrine's bavituximab cancer program, as this is the first of our three ongoing Phase II cancer trials to complete patient enrollment," said Steven W. King, president and CEO of Peregrine. "We will continue to assess patients in this study over the coming months and look forward to reporting updated preliminary results from the trial at the upcoming ASCO Annual Meeting."

In this trial's Simon two-stage design, 15 patients with advanced breast cancer were enrolled in the trial's first cohort. Ten of the 14 evaluable patients in this cohort demonstrated an objective tumor response according to RECIST criteria. These results compare favorably with historical response rates for docetaxel as solo therapy in advanced breast cancer patients and exceeded the pre-specified primary efficacy endpoint needed to expand enrollment in the trial. An additional 31 patients were then enrolled to achieve the planned study total of 46 patients overall.

Secondary obj
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
2. Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrines Fully Human Anti-PS Antibody in Prostate Cancer Model
3. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
4. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
5. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
6. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
9. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
10. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
11. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013 InspireMD, Inc. ... leader in embolic protection stents, today announced new ... ST Elevation Reperfusion) trial demonstrating that the MGuard ... drug eluting stents in all-cause mortality in ST ... the trial were presented at the InspireMD STEMI ...
(Date:5/23/2013)... Switzerland and DRESDEN, Germany ... Cenix BioScience, a leading preclinical contract research ... and high content-driven pharmacology, and Debiopharm Group™ (Debiopharm), ... a focus on the development of prescription drugs ... companion diagnostics, today announced that they have signed ...
(Date:5/22/2013)... Tenn. , May 22, 2013  Team Health ... of the largest suppliers of outsourced healthcare professional staffing ... in the United States , today ... 38th Annual Deutsche Bank Healthcare Conference held on May ... will begin at 8:00 AM eastern time.  Interested investors ...
Breaking Medicine Technology:InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 4InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 5Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers 2Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers 3Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers 4Team Health Holdings Inc. to Present at the 38th Annual Deutsche Bank Healthcare Conference 2
... GROVE, Minn., Feb. 18, 2011 Upsher-Smith Laboratories, Inc., ... announced recall of Jantoven® Warfarin Sodium, USP, 3 mg ... the same packaging line between May 17, 2010 and ... as a precautionary measure after a single bottle labeled ...
... Chilcott plc (Nasdaq: WCRX ) today announced that ... is scheduled to speak at the Citi 2011 Global Health ...   The presentation will be simultaneously webcast ... webcast available shortly thereafter at http://ir.wcrx.com/events.cfm . ...
Cached Medicine Technology:Upsher-Smith Laboratories Announces Expansion of Voluntary Nationwide Recall 2Upsher-Smith Laboratories Announces Expansion of Voluntary Nationwide Recall 3
(Date:5/23/2013)... some fast-food chains are required to provide calorie and ... kids who eat fast food at least twice a ... information than kids who eat fast food less often, ... likely to use the calorie information are girls and ... U.S. Centers for Disease Control and Prevention. The ...
(Date:5/23/2013)... Thompson HealthDay Reporter , , THURSDAY, May 23 ... millions to lower their cholesterol, but the medications also ... health through exercise, researchers say. A small group ... any significant fitness gains while taking a 40 milligram ... the drug but undergoing the same exercise regimen did ...
(Date:5/23/2013)... patients with a liposomal formulation of anthracycline-based chemotherapy at ... in high survival rates without causing any added heart ... published online today in Blood ... Hematology (ASH). , Acute myeloid leukemia (AML), ... is a blood cancer in which the bone marrow ...
(Date:5/23/2013)... influences soldier PTSD , Soldiers returning home from ... post-traumatic stress disorder if public support for a war ... or invalidation shapes the level of distress soldiers feel ... study involved two experiments that asked participants to exterminate ... having an actor show either interest or disgust for ...
(Date:5/23/2013)... A new study determined that children and adolescents ... to have clinically significant behavioral problems and psychiatric ... , a journal published by Wiley on behalf ... the importance of routine psychiatric evaluation for pediatric ... to anti-seizure medications and require epilepsy surgery. ...
Breaking Medicine News(10 mins):Health News:Too Few Kids Use Fast-Food Calorie Info, Study Finds 2Health News:Statins May Hamper Workout Results 2Health News:Statins May Hamper Workout Results 3Health News:Improved chemo regimen for childhood leukemia may offer high survival, no added heart toxicity 2Health News:Improved chemo regimen for childhood leukemia may offer high survival, no added heart toxicity 3Health News:Link between war support and PTSD, time it late in negotiations and courtship by narcissists 2Health News:Link between war support and PTSD, time it late in negotiations and courtship by narcissists 3Health News:Depression common among children with temporal lobe epilepsy 2
... Two ... biopharmaceutical environment. , ... Horsham, PA, USA (Vocus) June 5, 2009 -- The Drug Information ... longest running global, multidisciplinary conference featuring sessions and preconference tutorials on issues affecting drug ...
... techniques and bedtime habits may ease insomnia , ... sheep, maybe even taken sleeping pills. You might also ... a better night,s rest. , Chronic insomniacs who took ... about sleep hygiene, relaxation techniques and tips for stilling ...
... 5 Cardinal Health will hold an investor and ... EDT. The sole purpose is to discuss the year-to-date ... Health and CareFusion as standalone entities. , , ... the session and will explain pro forma financials for ...
... and serum lipid levels have improved in Swedish middle-aged ... mental stress, however, have increased significantly. These are the ... of Gothenburg, Sweden. The study is part of ... This study was initiated at the end of the ...
... /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (NASD OTC Bulletin ... the Fifth Annual Noble Financial Equity Conference at 9:15 ... Seminole Hard Rock Hotel in Hollywood, FL. Robert ... give a presentation regarding NeoGenomics, market positioning, financial performance, ...
... , Clearance Opens Door To Multi-Billion Dollar Home Skin ... Palomar Medical Technologies Inc. (Nasdaq: PMTI ), a ... today announced that it has become the first company to ... Food and Drug Administration (FDA) for a new, patented, home ...
Cached Medicine News:Health News:DIA 45th Annual Meeting Features Sessions Highlighting Wyeth v. Levine and Pandemic Influenza 2Health News:DIA 45th Annual Meeting Features Sessions Highlighting Wyeth v. Levine and Pandemic Influenza 3Health News:Can't Sleep? Try Online Therapy 2Health News:Cardinal Health Investor and Analyst Advisory 2Health News:Middle-aged women experience more stress but have lower blood pressure 2Health News:NeoGenomics to Present at Noble Financial's 5th Annual Equity Conference on Monday, June 8th 2Health News:Palomar Receives FDA Over-The-Counter Clearance for a Home Use Wrinkle Removal Laser Device 2Health News:Palomar Receives FDA Over-The-Counter Clearance for a Home Use Wrinkle Removal Laser Device 3Health News:Palomar Receives FDA Over-The-Counter Clearance for a Home Use Wrinkle Removal Laser Device 4
Streptavidin A-Beads are polydisperse 1.8 m paramagnetic particles covalently coupled with streptavidin. The paramagnetic particles remain in solution over extended periods of time. Mixing is require...
... method for isolating antibodies, antigens, lectins, ... affinity binding, while retaining biological activity. ... particles to separate biotinylated molecules from ... Beads from the suspension, an external ...
QuantumPlex is a bead kit for multiple analyte-detection research applications in flow cytometry. The beads may be analyzed with any standard cytometer and do not require the use of specialized softw...
... magnetic beads are 1 ... coupled to a form ... can be useful as ... including mRNA isolation and ...
Medicine Products: